1. Scrip
  2. >>Business
  3. >>Manufacturing

After Consent Decree, Wockhardt May Sell US Site Amid Wider Revamp

 
• By Anju Ghangurde

Wockhardt’s US arm Morton Grove Pharmaceuticals, which is bound by a consent decree of permanent injunction, discontinues production to undertake an “orderly closure” and potential sale of its Illinois site. Indian parent firm taps contract manufacturers to service US market.

Wockhardt's US arm discontinues operations at Illinois site • Source: Shutterstock

“We can’t change the direction of the wind, but we can adjust the sails,” Wockhardt Limited’s founder chairman Dr Habil Khorakiwala said at the firm’s annual general meeting earlier this month, referring in part to the challenging year gone by but also noting that the firm had adapted quickly and demonstrated resilience.

While some of the challenges may have been brought on by pandemic-related disruptions and supply chain turbulence, just over a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.